BPC-157 vs TB-500: What the Research Actually Shows
Both compounds appear regularly on research-vendor sites and in the same forums. The evidence base behind each is real but narrow, and the regulatory status is the same for both: not approved for human use. Here is what the studies actually say, where the gaps are, and what to look for when a vendor sells either one.
Side-by-side: what the evidence shows at a glance
The table below maps both compounds across the dimensions researchers and buyers ask about most. Rows cover mechanism, evidence quality, regulatory standing, and claims-risk. Read the compound-by-compound sections below for the full picture behind each cell.
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide derived from a partial sequence of Body Protection Compound, a gastric protein in humans | Synthetic analogue of the active region of Thymosin Beta-4 (TB4), a naturally occurring intracellular protein involved in actin regulation |
| Origin | Derived from human gastric juice protein; sequence identified in the 1990s by Sikiric et al. | Based on TB4's N-terminal tetrapeptide (Ac-SDKP) and its broader actin-binding domain; research lineage dates to the 1960s |
| Primary research focus | Soft-tissue and tendon healing, gut-barrier integrity, neuroprotection (all preclinical) | Tissue repair, cardiac recovery, hair follicle activation, angiogenesis (mostly preclinical; limited cardiac human trials) |
| Evidence level | Preclinical only Rodent and in-vitro models; no completed human RCTs as of 2026 | Mostly preclinical Small human pilot data in cardiac contexts only; no large RCTs for tissue repair claims |
| FDA status | Not approved Research compound. Not FDA-approved for human use, diagnosis, or treatment | Not approved Research compound. Not FDA-approved for human use, diagnosis, or treatment |
| Commonly stacked (in research literature) | Often studied alongside GHK-Cu in tissue-healing models; stacking not studied in controlled human trials | Often co-investigated with IGF-1 in muscle and cardiac recovery models; no controlled human stacking data |
| Claims-risk | High Vendors frequently publish injury-recovery language that implies human treatment | High Vendors frequently publish performance and cardiac-benefit language beyond what human data supports |
BPC-157: what the research actually shows
The preclinical case
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide. The sequence was isolated from human gastric juice protein by Sikiric and colleagues in Croatia, and it has been studied in rodent models since the mid-1990s. The preclinical literature is substantial: studies in rats and mice have shown accelerated tendon repair, improved anastomosis healing after bowel surgery, protection against NSAID-induced gut damage, and neuroprotective effects in various injury models.
The mechanism proposed in most studies involves upregulation of growth-hormone receptors at local injury sites and modulation of nitric oxide pathways. Some studies also point to effects on VEGF (vascular endothelial growth factor), which could explain observed improvements in wound vascularization in animal models.
This is real science. The preclinical signal is consistent enough that it has attracted legitimate research interest for over two decades. The problem is the translation gap: rodent pharmacokinetics are not human pharmacokinetics, and no completed, peer-reviewed randomized controlled trial in humans has established efficacy or safety for BPC-157 at any dose or indication as of the time of this review.
Key evidence gap for BPC-157: The strongest existing data comes from rat-model tendon and gut studies. Extrapolating those results to human clinical outcomes is not supported by current evidence. Vendors who present this research as proof of human benefit are overstating what the studies show.
Regulatory status
BPC-157 is not approved by the U.S. Food and Drug Administration for any human use. It is not an FDA-approved drug, not a dietary supplement, and not cleared for clinical application. The FDA has issued warning letters to at least two vendors in recent years for marketing BPC-157 with human health claims. In 2021, the FDA clarified that BPC-157 cannot be sold as a dietary supplement ingredient and cannot be compounded for human use under 503A or 503B pharmacy frameworks. Vendors currently selling it are doing so as a "research chemical" under legal frameworks that prohibit labeling or marketing for human use.
TB-500: what the research actually shows
The preclinical case
TB-500 is a synthetic peptide analogue of Thymosin Beta-4 (TB4), a protein found in virtually all nucleated human cells. TB4 plays a structural role in actin polymerization and has been studied for decades in the context of wound healing, cardiac repair, and hair follicle regulation. TB-500 specifically refers to a fragment (or sometimes the full synthetic analogue) marketed in the research-compound space.
The preclinical signal for TB4 and its analogues is genuinely broad. Animal studies have documented accelerated corneal healing, reduced post-infarction cardiac scarring, improved skeletal muscle repair, and stimulation of hair follicle stem cells. The cardiac research has been particularly active, with multiple studies in rodent and porcine infarction models showing meaningful reductions in infarct size when TB4 is administered post-injury.
Human data is slightly more present for TB4 than for BPC-157, but it is still limited. A small Phase I/II trial (RegeneRx Biopharmaceuticals, 2014) evaluated TB4 in patients with dry eye syndrome and found a favorable safety profile. A separate small pilot evaluated topical TB4 for non-healing neurotrophic corneal ulcers. Neither trial covered the systemic tissue-repair or performance-enhancement claims that dominate vendor marketing.
What the human data actually covers: The available human trials for Thymosin Beta-4 focused on topical ophthalmic applications at low doses. Systemic injection for tissue repair, athletic recovery, or cardiac benefit in otherwise healthy individuals has not been studied in any completed human RCT.
Regulatory status
TB-500 (as a research peptide analogue of TB4) is not FDA-approved for any human use. Thymosin Beta-4 itself has been studied in FDA-regulated trials under Investigational New Drug (IND) applications, which means it was treated as a drug requiring approval, not a supplement or research chemical available for open sale. Vendors selling synthetic TB4 analogues as research compounds are operating in a space the FDA has not formally cleared for human use, and several have received scrutiny for language implying clinical application.
Which the evidence supports more
A narrow, honest read of the data
Neither compound has sufficient human evidence to declare a clear winner for any clinical application. If forced to compare the two evidence bases, TB-500 has a marginal edge in human data volume, owing to the ophthalmic trials run under IND designation. That data does not extend to the systemic or performance contexts most vendors advertise.
BPC-157 has a larger volume of preclinical literature across more tissue types, but the complete absence of human RCT data means researchers cannot verify that the rodent results translate. The preclinical signal is interesting. It is not proof of human efficacy.
Both compounds are legitimately interesting research targets. Neither one is ready for the "proven treatment" framing that appears on most vendor product pages. A researcher evaluating either compound should weigh the animal-model data as hypothesis-generating, not as efficacy evidence for human outcomes.
How to vet a vendor selling either compound
The research-compound space has a documentation problem. Because neither BPC-157 nor TB-500 is FDA-regulated for human sale, there is no mandatory testing standard. What separates a credible vendor from a problematic one is self-imposed transparency, and the following checks reveal it quickly.
COA fundamentals
- Batch-specific COA: The certificate of analysis should reference the same lot or batch number printed on the vial. A generic, undated COA with no batch identifier is a sticker, not a document.
- Named third-party laboratory: The testing lab should be identifiable and verifiable. "Independently tested" with no lab name is not transparency.
- HPLC purity plus mass spectrometry identity: Purity alone (HPLC) confirms the percentage of the product that is peptide. Mass spectrometry (MS or LC-MS) confirms the peptide is actually what the label claims. Both are needed.
- Date of test: A COA dated more than 18 months ago for product currently in inventory is a documentation gap, not a pass.
Claims-risk screening
- Any vendor page describing dosing protocols, injection instructions, or reconstitution guidance is marketing for human use. This is a regulatory risk signal regardless of "for research only" disclaimers buried in fine print.
- Language like "heals tendons," "repairs muscle," or "supports recovery" in a product description implies treatment claims. For a compound with no FDA approval, this is prohibited marketing.
- Vendors who cite specific preclinical studies accurately and note that results have not been replicated in humans are demonstrating more intellectual honesty than those who strip the context.
High-risk signal: A vendor page for BPC-157 or TB-500 that includes a dosing chart, cycle recommendations, or injection-volume guidance is not operating as a research supplier. It is marketing an unapproved drug for human use, which puts both the vendor and the buyer in a difficult regulatory position.
Vendor documentation checklist
Before purchasing from any vendor selling BPC-157, TB-500, or related peptides, confirm the following:
- COA is batch-linked, not generic
- Third-party lab is named and traceable
- Both purity (HPLC) and identity (MS) are tested
- No human dosing, protocol, or injection language on product pages
- Refund and quality terms are stated without requiring a support email to find
- No disease-treatment or injury-cure claims
Vetted vendors for research use
Our vendor index screens documentation against the checklist above. Vendors below passed our COA audit at the time of review. Scores are re-checked monthly. We do not accept payment for rank placement.
Frequently asked questions
- Can BPC-157 and TB-500 be stacked for research purposes?
- Both compounds appear together in some rodent studies, and they are frequently discussed together in research forums. However, no controlled human study has examined the combination. The theoretical rationale in animal models relates to complementary pathways: BPC-157's proposed nitric oxide and growth-factor modulation alongside TB4's actin-regulation effects. Researchers interested in both compounds should note that combined-use data in humans is entirely absent from the peer-reviewed literature as of 2026.
- What does "research compound not approved for human use" mean in practice?
- It means the compound has not gone through the FDA's drug approval process (or equivalent international regulatory processes) for any human indication. It has not been evaluated for safety, efficacy, or appropriate dosing in humans through the required clinical trial stages. Vendors may sell such compounds for in-vitro (cell culture) or laboratory animal research. They are legally prohibited from marketing them with human health claims, dosing instructions, or treatment language.
- How do I know if a vendor's COA is real and not fabricated?
- Look for the testing laboratory's name and accreditation number on the COA. Search the lab directly to confirm it exists, holds appropriate ISO or CLIA accreditation, and performs the specific tests listed. Some labs publish results portals where you can verify a report by lot number. A COA that cannot be cross-referenced to an identifiable, accredited laboratory is not independently verified, regardless of what the document header says.
Sources
Sources are listed by publication date, most recent first. All cited studies are peer-reviewed unless noted.
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153318
- Gwyer D, Wragg NM, Wilson SL. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell and Tissue Research. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
- Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
- RegeneRx Biopharmaceuticals. "Phase II Clinical Trial of Thymosin Beta 4 Eye Drops for Dry Eye Syndrome." ClinicalTrials.gov Identifier: NCT01248026. Results posted 2014.
- Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo." Experimental Eye Research. 2001;72(5):605-608. doi:10.1006/exer.2001.0943
- U.S. Food and Drug Administration. "FDA warns consumers about health risks with unapproved BPC-157 products." FDA Safety Alert. October 2021. fda.gov
- Ehrlich HP, et al. "Thymosin beta 4 enhances repair of fetal rabbit tendons in organ culture." Wound Repair and Regeneration. 1994;2(1):49-56. doi:10.1046/j.1524-475X.1994.20111.x
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
